Organon patent expiration

1. Clarinex patent expiration

CLARINEX IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7211582 ORGANON Methods for treating urticaria using descarboethoxyloratadine
Dec, 2014

(9 years ago)

US7214684 ORGANON Methods for the treatment of allergic rhinitis
Dec, 2014

(9 years ago)

US7214683 ORGANON Compositions of descarboethoxyloratadine
Dec, 2014

(9 years ago)

US5607697 ORGANON Taste masking microparticles for oral dosage forms
Jun, 2015

(9 years ago)

US7214684

(Pediatric)

ORGANON Methods for the treatment of allergic rhinitis
Jun, 2015

(9 years ago)

US7214683

(Pediatric)

ORGANON Compositions of descarboethoxyloratadine
Jun, 2015

(9 years ago)

US7211582

(Pediatric)

ORGANON Methods for treating urticaria using descarboethoxyloratadine
Jun, 2015

(9 years ago)

US5607697

(Pediatric)

ORGANON Taste masking microparticles for oral dosage forms
Dec, 2015

(8 years ago)

US7405223 ORGANON Treating allergic and inflammatory conditions
Jul, 2019

(5 years ago)

US6100274 ORGANON 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
Jul, 2019

(5 years ago)

US6100274

(Pediatric)

ORGANON 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
Jan, 2020

(4 years ago)

US7405223

(Pediatric)

ORGANON Treating allergic and inflammatory conditions
Jan, 2020

(4 years ago)

US7618649 ORGANON Extended release oral dosage composition
Dec, 2020

(3 years ago)

US7618649

(Pediatric)

ORGANON Extended release oral dosage composition
Jun, 2021

(3 years ago)




Drugs and Companies using DESLORATADINE ingredient

Market Authorisation Date: 14 July, 2005

Treatment: Treatment of chronic idiopathic urticaria; Treatment of allergic rhinitis; Administering desloratadine to treat the symptoms of perennial allergic rhinitis, seasonal allergic rhinitis, or chronic idio...

Dosage: TABLET, ORALLY DISINTEGRATING; TABLET

How can I launch a generic of CLARINEX before it's drug patent expiration?
More Information on Dosage

CLARINEX family patents

Family Patents

2. Clarinex D 24 Hour patent expiration

CLARINEX D 24 HOUR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214684 ORGANON Methods for the treatment of allergic rhinitis
Dec, 2014

(9 years ago)

US7214683 ORGANON Compositions of descarboethoxyloratadine
Dec, 2014

(9 years ago)

US7214684

(Pediatric)

ORGANON Methods for the treatment of allergic rhinitis
Jun, 2015

(9 years ago)

US7214683

(Pediatric)

ORGANON Compositions of descarboethoxyloratadine
Jun, 2015

(9 years ago)

US6100274 ORGANON 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
Jul, 2019

(5 years ago)

US6100274

(Pediatric)

ORGANON 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
Jan, 2020

(4 years ago)

US7618649 ORGANON Extended release oral dosage composition
Dec, 2020

(3 years ago)

US7618649

(Pediatric)

ORGANON Extended release oral dosage composition
Jun, 2021

(3 years ago)

US6979463 ORGANON Stable extended release oral dosage composition
Mar, 2022

(2 years ago)

US7820199 ORGANON Stable extended release oral dosage composition
Mar, 2022

(2 years ago)

US7820199

(Pediatric)

ORGANON Stable extended release oral dosage composition
Sep, 2022

(1 year, 11 months ago)




Drugs and Companies using DESLORATADINE; PSEUDOEPHEDRINE SULFATE ingredient

Market Authorisation Date: 03 March, 2005

Treatment: Treatment of allergic rhinitis; A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

CLARINEX D 24 HOUR family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Fosamax patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6090410 ORGANON Dry mix formulation for bisphosphonic acids
Dec, 2012

(11 years ago)

US5681590 ORGANON Dry mix formulation for bisphosphonic acids
Dec, 2012

(11 years ago)

US5358941 ORGANON Dry mix formulation for bisphosphonic acids with lactose
Dec, 2012

(11 years ago)

US6194004 ORGANON Dry mix formulation for bisphosphonic acids
Dec, 2012

(11 years ago)

US5681590

(Pediatric)

ORGANON Dry mix formulation for bisphosphonic acids
Jun, 2013

(11 years ago)

US6090410

(Pediatric)

ORGANON Dry mix formulation for bisphosphonic acids
Jun, 2013

(11 years ago)

US5358941

(Pediatric)

ORGANON Dry mix formulation for bisphosphonic acids with lactose
Jun, 2013

(11 years ago)

US6194004

(Pediatric)

ORGANON Dry mix formulation for bisphosphonic acids
Jun, 2013

(11 years ago)




Drugs and Companies using ALENDRONATE SODIUM ingredient

Market Authorisation Date: 25 April, 1997

Treatment: NA

Dosage: TABLET

How can I launch a generic of FOSAMAX before it's drug patent expiration?
More Information on Dosage

FOSAMAX family patents

Family Patents

4. Implanon patent expiration

IMPLANON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9757552 ORGANON Applicator for inserting an implant
Jul, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 31, 2014

Drugs and Companies using ETONOGESTREL ingredient

Market Authorisation Date: 17 July, 2006

Treatment: Prevention of pregnancy

Dosage: IMPLANT

More Information on Dosage

IMPLANON family patents

Family Patents

5. Liptruzet patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5969156 ORGANON Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
Jul, 2016

(8 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5846966 ORGANON Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
Sep, 2013

(10 years ago)

US5846966

(Pediatric)

ORGANON Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
Mar, 2014

(10 years ago)

US5686104 ORGANON Stable oral CI-981 formulation and process of preparing same
Nov, 2014

(9 years ago)

US5686104

(Pediatric)

ORGANON Stable oral CI-981 formulation and process of preparing same
May, 2015

(9 years ago)

USRE42461 ORGANON Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Oct, 2016

(7 years ago)

US5969156

(Pediatric)

ORGANON Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
Jan, 2017

(7 years ago)

USRE42461

(Pediatric)

ORGANON Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Apr, 2017

(7 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) May 03, 2016

Drugs and Companies using ATORVASTATIN CALCIUM; EZETIMIBE ingredient

Market Authorisation Date: 03 May, 2013

Treatment: For the treatment of primary hyperlipidemia, mixed hyperlipidemia or homozygous familial hypercholesterolemia

Dosage: TABLET

More Information on Dosage

LIPTRUZET family patents

Family Patents

6. Maxalt-mlt patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5602162

(Pediatric)

ORGANON Imidazole, triazole and tetrazole derivatives
Jul, 2012

(12 years ago)

US5298520

(Pediatric)

ORGANON Triazole containing indole derivatives
Dec, 2012

(11 years ago)

US5457895 ORGANON Method of identifying freeze-dried dosage forms
Oct, 2013

(10 years ago)

US5457895

(Pediatric)

ORGANON Method of identifying freeze-dried dosage forms
Apr, 2014

(10 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 16, 2014
Pediatric Exclusivity(PED) Jun 16, 2015

Drugs and Companies using RIZATRIPTAN BENZOATE ingredient

Market Authorisation Date: 29 June, 1998

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING

How can I launch a generic of MAXALT-MLT before it's drug patent expiration?
More Information on Dosage

MAXALT-MLT family patents

Family Patents

7. Nexplanon patent expiration

NEXPLANON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8888745 ORGANON Applicator for inserting an implant
Aug, 2026

(1 year, 11 months from now)

US10821277 ORGANON Kit for and method of assembling an applicator for inserting an implant
May, 2027

(2 years from now)

US8722037 ORGANON X-ray visible drug delivery device
Sep, 2027

(3 years from now)

US9757552 ORGANON Applicator for inserting an implant
Jul, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 31, 2014

Drugs and Companies using ETONOGESTREL ingredient

Market Authorisation Date: 17 July, 2006

Treatment: Prevention of pregnancy

Dosage: IMPLANT

More Information on Dosage

NEXPLANON family patents

Family Patents

8. Propecia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5886184 ORGANON Finasteride processes
Nov, 2012

(11 years ago)

US5547957 ORGANON Method of treating androgenic alopecia with 5-α reductase inhibitors
Oct, 2013

(10 years ago)

US5571817 ORGANON Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
Nov, 2013

(10 years ago)




Drugs and Companies using FINASTERIDE ingredient

Market Authorisation Date: 19 December, 1997

Treatment: Treating male pattern baldness with 0.05 to 3.0mg/day; Treatment of androgenic alopecia by oral administration drug substance

Dosage: TABLET

How can I launch a generic of PROPECIA before it's drug patent expiration?
More Information on Dosage

PROPECIA family patents

Family Patents

9. Proscar patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5886184 ORGANON Finasteride processes
Nov, 2012

(11 years ago)

US5942519 ORGANON Prevention of precipitated acute urinary retention
Oct, 2018

(5 years ago)




Drugs and Companies using FINASTERIDE ingredient

Market Authorisation Date: 19 June, 1992

Treatment: Treating precipitated acute urinary retention with finasteride

Dosage: TABLET

How can I launch a generic of PROSCAR before it's drug patent expiration?
More Information on Dosage

PROSCAR family patents

Family Patents

10. Singulair patent expiration

SINGULAIR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5565473

(Pediatric)

ORGANON Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
Aug, 2012

(12 years ago)

US8007830 ORGANON Granule formation
Oct, 2022

(1 year, 10 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Mar 26, 2015

Drugs and Companies using MONTELUKAST SODIUM ingredient

Market Authorisation Date: 20 February, 1998

Treatment: Asthma

Dosage: TABLET; TABLET, CHEWABLE; GRANULE

How can I launch a generic of SINGULAIR before it's drug patent expiration?
More Information on Dosage

SINGULAIR family patents

Family Patents

11. Vytorin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5846966 ORGANON Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
Sep, 2013

(10 years ago)

US5846966

(Pediatric)

ORGANON Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
Mar, 2014

(10 years ago)

USRE37721 ORGANON Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Oct, 2016

(7 years ago)

USRE42461 ORGANON Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Oct, 2016

(7 years ago)

USRE37721

(Pediatric)

ORGANON Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Apr, 2017

(7 years ago)

USRE42461

(Pediatric)

ORGANON Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Apr, 2017

(7 years ago)




Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Dec 05, 2011
M(M-109) Jan 24, 2015

Drugs and Companies using EZETIMIBE; SIMVASTATIN ingredient

Market Authorisation Date: 23 July, 2004

Treatment: Treatment of primary hypercholesterolemia, mixed hyperlipidemia and/or homozygous familial hypercholesterolemia (hofh); To reduce plasma cholesterol levels in a mammal

Dosage: TABLET

How can I launch a generic of VYTORIN before it's drug patent expiration?
More Information on Dosage

VYTORIN family patents

Family Patents

12. Zetia patent expiration

ZETIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5846966 ORGANON Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
Sep, 2013

(10 years ago)

US5846966

(Pediatric)

ORGANON Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
Mar, 2014

(10 years ago)

USRE42461 ORGANON Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Oct, 2016

(7 years ago)

USRE37721 ORGANON Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Oct, 2016

(7 years ago)

USRE42461

(Pediatric)

ORGANON Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Apr, 2017

(7 years ago)

USRE37721

(Pediatric)

ORGANON Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Apr, 2017

(7 years ago)

US7030106 ORGANON Sterol absorption inhibitor compositions
Jan, 2022

(2 years ago)

US7030106

(Pediatric)

ORGANON Sterol absorption inhibitor compositions
Jul, 2022

(2 years ago)

US7612058 ORGANON Methods for inhibiting sterol absorption
Oct, 2025

(1 year, 1 month from now)

US7612058

(Pediatric)

ORGANON Methods for inhibiting sterol absorption
Apr, 2026

(1 year, 7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Dec 05, 2011
M(M-109) Jan 24, 2015

Drugs and Companies using EZETIMIBE ingredient

Market Authorisation Date: 25 October, 2002

Treatment: To reduce elevated total-c, apo b, and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe in combination with a statin; To reduce elevated total-c, ldl-c, apo b and non-h...

Dosage: TABLET

How can I launch a generic of ZETIA before it's drug patent expiration?
More Information on Dosage

ZETIA family patents

Family Patents